SCHEMBL2277607

SCHEMBL2277607

COCCNC(=O)c1cccc(C=CC(=O)c2c(O)cc(C)[nH]c2=O)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 7/20 0.40
SMN1; SMN2 Q16637 5/20 0.40
HPGD P15428 4/20 0.40
MAPT P10636 3/20 0.40
ALDH1A1 P00352 3/20 0.40
PAX8 Q06710 1/20 0.40
PIM1 P11309 1/20 0.38
KDM4E B2RXH2 4/20 0.38
HTT P42858 4/20 0.37
NPSR1 Q6W5P4 2/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
POLB P06746 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
TP53 P04637 2/20 0.35
CYP1A2 P05177 2/20 0.35
CYP2C19 P33261 2/20 0.35
RAB9A P51151 2/20 0.35
NPC1 O15118 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2277602 1.00 LMNA (0.40) LMNASMN1; SMN2HPGDMAPTALDH1A1
SCHEMBL13403294 0.83 MEN1 (0.51) SMN1; SMN2HPGDMAPTALDH1A1KDM4E
SCHEMBL12374855 0.82 MEN1 (0.48) LMNASMN1; SMN2HPGDMAPTALDH1A1
SCHEMBL2280683 0.81 LMNA (0.43) LMNASMN1; SMN2HPGDMAPTPAX8
SCHEMBL2280689 0.81 LMNA (0.43) LMNASMN1; SMN2HPGDMAPTPAX8
SCHEMBL13818097 0.80 PADI4 (0.40) SMN1; SMN2HPGDMAPTALDH1A1PIM1
SCHEMBL2274871 0.80 LMNA (0.50) LMNASMN1; SMN2HPGDMAPTALDH1A1
SCHEMBL2274875 0.80 LMNA (0.50) LMNASMN1; SMN2HPGDMAPTALDH1A1
SCHEMBL2284238 0.77 LMNA (0.41) LMNASMN1; SMN2HPGDMAPTALDH1A1
SCHEMBL12374701 0.77 ALDH1A1 (0.40) SMN1; SMN2HPGDMAPTALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989478-B2 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-02 US disclosed
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-09-21 US disclosed
EP-1671948-A1 CINNAMOYL COMPOUND AND USE OF THE SAME Sumitomo Chemical Company, Limited (JP) 2006-06-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis COL2A1, COL1A1, COL14A1 LMNA 537/4885SMN1; SMN2 3766/4885HPGD 1011/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.